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Abstract
Background: Small, dense low-density lipoprotein (sd-LDL) and glycated LDL (g-LDL) have been associated with
cardiovascular disease (CVD) in chronic kidney disease (CKD) in patients>60 years of age. Since young adult and paediatric
patients have shorter exposure to Framingham-type risk factors, our study aims to determine whether younger CKD
patients exhibit the same sd-LDL and g-LDL pattern.
Methods: After ethics board approval, this cross-sectional study was conducted at two universities with 44 patients
(mean6 standard deviation age 12.66 4.9, range 2–24 years) with CKD stage of 1–5. Laboratory parameters studied were
Cystatin C (CysC), CysC estimated glomerular filtration rate (eGFR) (calculated from the Filler formula), sd-LDL, g-LDL and
albumin. Lipid samples were measured for sd-LDL and g-LDL using ELISA. Non-linear correlation analysis was performed to
determine the relationship between g-LDL, sd-LDL and eGFR. Clinical Trials Registration is at clinicaltrials.gov,
NCT02126293, https://clinicaltrials.gov/ct2/show/NCT02126293.
Results: Triglycerides, but not total cholesterol and calculated LDL, were associated with CKD stages (ANOVA P¼0.0091).
As in adults, sd-LDL was significantly associated with CKD stages (ANOVA P¼0.0133), CysC eGFR (r¼0.6495, P<0.00001),
and body mass index (r¼0.3895, P¼0.0189), but not with age. By contrast, there was no significant correlation between g-
LDL and CKD stages or CysC eGFR (P¼0.9678).
Conclusions: Our study demonstrates that only triglycerides and sd-LDL were associated with CKD stages in this
young cohort without confounding Framingham-type CVD risk factors. While larger studies are needed, this study
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suggests that lowering sd-LDL levels may be a potential target to ameliorate the long-term CVD risks in paediatric
CKD patients.
Key words: cardiovascular risk, chronic kidney disease, disordered lipids, Framingham-type risk factors, small dense LDL,
triglycerides
Introduction
Lipoprotein transfer proteins are complex particles composed
of 80–100 proteins per particle [organized by a single apolipopro-
tein B for low-density lipoprotein (LDL) and larger particles] that
increase the availability of fats and allow them to be taken up
by the cells in the body via receptor-mediated endocytosis [1, 2].
A single LDL particle is about 220–275 angstroms in diameter
and typically transports 3000 to 6000 fat molecules/particle,
which vary in size depending on the number and mix of fat mol-
ecules contained within [3]. The lipids that are transported by
LDL particles include all fat molecules with cholesterol, phos-
pholipids and triglycerides. The proportions of these fats vary
considerably. LDL particles pose a risk for cardiovascular dis-
ease (CVD) when they invade the endothelium and become oxi-
dized, since the oxidized forms are more easily retained by the
proteoglycans [1, 3]. Small, dense (sd-LDL) and glycated (g-LDL)
LDL have been associated with CVD risk [4].
It has long been known that patients with chronic kidney
disease (CKD) usually have disordered lipid profiles and tend to
succumb to cardiovascular events [5, 6]. The impaired lipid
metabolism seen in patients with CKD impacts the cardiovascu-
lar system in several ways, namely by preventing the formation
of high-density lipoprotein (HDL), impairing reverse cholesterol
transport, intensifying the prevailing systemic oxidative stress
and inflammation, and increasing the risk of atherosclerotic
cardiovascular disease and CKD progression [7]. Cyclically, this
HDL deficiency and dysfunction contributes to CKD progression
by promoting glomerulosclerosis and tubular damage and dys-
function [8, 9]. Such patients also tend to have an increase in tri-
glycerides [10]. Although cardiovascular morbidity has been
linked to LDL, some LDL is favourable as it serves as the main
carrier for the transport of cholesterol to the cells, and LDL lev-
els may be normal in patients with CVD [11] and may even be
reduced in CKD patients [10]. LDL consists of several subclasses
with distinct sizes, densities and physicochemical compositions
[11]. sd-LDL [11] and g-LDL [4] have specifically been associated
with cardiovascular disease. More recently, a specific pattern of
elevated oxidized LDL [10] and sd-LDL was described with
worsening CKD [12], and sd-LDL levels were associated with
mortality [13]. Notably, these studies were performed in typical
adult CKD patients over 60 years of age, where typical
Framingham-type risk factors may confound CKD-specific
changes. Framingham risk factors include age, gender, total and
HDL cholesterol, smoking, diabetes, systolic blood pressure and
treatment for high blood pressure [14]. The similarities and dif-
ferences between the lipid profiles of patients with metabolic
syndrome and patients with CKD have been previously high-
lighted [15]. We were interested in seeing whether children
would also exhibit the sd-LDL elevation found with a worsening
estimated glomerular filtration rate (eGFR) where Framingham-
type risk factors are typically absent. We measured sd-LDL and
g-LDL in children and adolescents with CKD Stages 1–5 who
were ‘not on dialysis’. We hypothesized that the concentration
of sd-LDL would increase with worsening kidney function while
g-LDL would remain unaffected because children and young
adults with CKD typically do not have diabetes or other more
conventional cardiovascular risk factors.
Materials and methods
Methods
The study adhered to the Declaration of Helsinki. The Research
Ethics Boards of Western and McMaster Universities approved
the study as part of a cross-sectional study of biomarkers of
CVD in children and young adults with CKD (Western Ontario:
REB#16962E, McMaster University: REB#12-537). The goal of the
original study was to describe FGF23 and other biomarkers in
relationship to renal function in children and young adults with
CKD and comprised 157 patients from London and Hamilton. As
an ancillary study, we conducted this cross-sectional sub-study
of 44 children, adolescents and young adults, who were not on
dialysis, and were recruited between 17 March 2010 and 28
October 2013 with CKD from Stages 1 to 5 (CKD was diagnosed
according to the 2012 KDIGO clinical practice guideline [16]).
They had blood work performed as part of their regular assess-
ment and had abundant serum. The original inclusion criteria
for the study period that determined the sample size were
patients from 1.5 years to 50 years with CKD Stages 1–5 who
require regular assessments to measure their renal function
and bone status. However, for the purposes of this study, we
excluded patients>25 years of age. Additional exclusion criteria
included patients who were younger than 1.5 years of age
because of the developmental changes of GFR. Clinical Trials
Registration is at clinicaltrials.gov, NCT02126293, https://clinical
trials.gov/ct2/show/NCT02126293.
Materials
The samples for the lipid study were selected at random based
on the abundant samples available in the repository at the
Translational Research Centre at the London Health Sciences
Centre [17] and in an effort to have an even distribution of
patients with CKD Stages 1–5. Other laboratory parameters that
were necessary for our analysis were taken from our database
(Microsoft Excel for Mac v.14.6.8) or from our centre’s electronic
medical chart database. Laboratory parameters that were used
for this study included Cystatin C (CysC), CysC eGFR, sd-LDL, g-
LDL and albumin. We calculated CysC eGFR using the Filler for-
mula [18] and body mass index (BMI) from the patients’ meas-
ured height and weight. Even though BMI is age-dependent in
children, BMI values were not converted to z-scores because
there are no z-scores available for young adults. sd-LDL and g-
LDL were measured using commercially available ELISA kits by
MyBioSource, Inc., San Diego, CA , USA. The sd-LDL was meas-
ured with the qualitative sandwich ELISA ‘Human small dense
low density lipoprotein (sLDL) ELISA Kit (Cat.No: MBS700740)’
using undiluted original serum samples, with a detection range
between 0.312 and 20 nmol/mL. The g-LDL was measured with
the qualitative sandwich ELISA ‘GLDL ELISA KIT (Cat.No:
MBS020040)’ using undiluted original serum samples. The
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detection range is 0.25 –8 nmol/mL. Standards were used as per
the manufacturer’s instructions. As there were some inconsis-
tencies with the expected concentrations and those of the
standards, we report the ELISA readings as relative units (rU).
Statistical analysis
Contiguous data were analysed for normal distribution using
the Kolmogorov Smirnov test. For normally distributed parame-
ters, parametric and otherwise non-parametric statistical com-
parator tests were applied based on the distribution of the data
using GraphPad Prism v.5.0f and Microsoft Excel version 15.34
for Mac. Data are expressed as average61 standard deviation
(SD) for normally distributed parameters, and median (25th,
75th percentile) otherwise. As appropriate for the distribution,
linear or non-linear correlation analysis was performed to
assess the relationship between age, eGFR, sd-LDL and g-LDL. A
P-value of <0.05 was considered significant for all analyses.
Results
The primary diagnoses of our study cohort are given in Table 1.
Patients ranged in age from 2 to 24 years, with a mean age of
12.664.9 years; 40 patients were18 years old, and 4 were
between the ages of 19 and 24. Of these patients, 23 were male
and 21 were female. CKD stage distribution was as follows:
Stage 1¼ 4, Stage 2¼ 7, Stage 3¼ 13, Stage 4¼ 8, Stage 5¼ 12.
Average age (61 SD) was 14.16 2.5 years for CKD Stage 1,
11.163.6 years for CKD Stage 2, 12.364.3 years for CKD Stage 3,
20.466.5 for CKD Stage 4 and 13.865.9 years for CKD Stage 5.
Median BMI and laboratory values are given in Table 2. Neither
sd-LDL nor eGFR correlated with age. Total cholesterol, LDL
cholesterol, HDL cholesterol and triglycerides are summarized
in Figure 1. We also provide the sd-LDL and g-LDL
measurements in Figure 1. As seen, only very few patients had
elevated total cholesterol or LDL cholesterol levels, or decreased
HDL cholesterol levels. Only triglycerides were associated with
the stage of CKD (ANOVA P¼ 0.0091). Figure 2 shows the rela-
tionship of sd-LDL and g-LDL with CysC eGFR. Interestingly, sd-
LDL cholesterol, but not g-LDL cholesterol, was associated with
both the CysC eGFR (Spearman r¼0.6495, P < 0.00001) and the
stage of CKD (ANOVA P¼ 0.0133) (Figures 1 and 2). The patients’
BMI also correlated with sd-LDL (Spearman r ¼0.3895,
P¼ 0.0189). There was no significant correlation between CysC
eGFR and g-LDL (Figure 2, right).
Median microalbumin to creatinine ratio was 19.7 g/mol
(range 0.2–44.6, interquartile range 2.35–46.5 g/mol). Data were
not normally distributed. Interestingly, microalbumin/creati-
nine ratio correlated significantly with sd-LDL (P¼ 0.0033) and
with triglycerides (P¼ 0.0441). Using multivariate analysis and
adjusting for microalbumin, CysC eGFR remained significant
(P¼ 0.0135). We also adjusted for BMI and for age. Both of these
were not significant in the multivariate analysis. Therefore,
only CysC eGFR and microalbuminuria affected sd-LDL.
Discussion
In an effort to unravel the cardiovascular aetiology and out-
comes that pose the greatest threat to patients with CKD, pre-
vious studies in adults have examined the use of lipid
biomarkers to predict and monitor patient CVD outcomes, since
traditional risk factors do not fully explain the high incidence of
CVD in CKD, and traditional lipid measures do not sufficiently
predict these outcomes in patients with CKD [19–22]. This effort,
however, may be confounded by the Framingham factors seen
in adults that are absent in children.
As predicted, the lack of correlation between CysC eGFR and
g-LDL seen in our study suggests that traditional Framingham-
like cardiovascular risk factors such as glycosylation may not be
important factors in the cardiovascular morbidity and mortality
of non-diabetic CKD patients. The sd-LDL, however, was associ-
ated with CysC eGFR, stage of CKD and BMI, thereby confirming
adult data [23] and solidifying the notion that a CKD patient’s
sd-LDL level may be a very important atherogenic risk factor,
and can be used as a predictor for CVD morbidity and mortality
[12, 19, 24–26]. The results of this study also conformed to the
significantly higher levels of sd-LDL compared with LDL seen in
patients with coronary artery disease, and this relationship’s
association with the incidence of cardiovascular events inde-
pendently of LDL itself [27, 28]. Similar to past studies [29], our
study also suggests that sd-LDL may be a more suitable marker
than LDL for measuring CVD, which is particularly important
considering the most recent paediatric/adolescent guidelines
that only use LDL as a marker for dyslipidaemia and atheroscle-
rosis [30, 31].
Our study has several limitations, including its retrospective
design, the wide age range of our patients and the modest sam-
ple size. Absolute BMI was used, and it is possible that the corre-
lation between BMI and sd-LDL was therefore confounded by
age, although age was not correlated with sd-LDL. A strength of
our study is the use of CysC eGFR rather than Schwartz eGFR;
the former is a more accurate biomarker for kidney function,
and by the virtual elimination of Framingham factor confound-
ers, a trait that cannot be replicated in adult studies. The for-
mula used for calculating the eGFR is the only formula that has
been validated in both children and adults [32].
Without the aforementioned confounding Framingham risk
factors seen in adults, these results bring us closer to
Table 1. Patients breakdown by CKD aetiology
CKD aetiology
Hereditary Acquired
Renal dysplasia 5 Renal transplant 13
Genetic conditionsa 12 Haemolytic uraemic
syndrome
4
Obstructive uropathy 3 Spina bifida and
neurogenic bladder
2
Idiopathic Fanconi
syndrome
1 Glomerulonephritis,
FSGS
3
Ischaemic acute
kidney injury
1
aSuch as autosomal recessive polycystic kidney disease, nephronopthisis and
syndromes associated with renal dysplasia.
FSGS, focal segmental glomerulosclerosis.
Table 2. Median laboratory values
Blood parameter Median (Q1, Q3) Unit
BMI 19.0264.35 kg/m2
CysC 2.28 (1.25–4.61) mg/L
CysC eGFR 36.5 (16.75–71.25) mL/min/1.73 m2
Albumin 43.5 (40.8–46.0) g/L
g-LDL 0.23 (0.14–0.59) rU
sd-LDL 2.47 (1.74–3.98) rU
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determining a mechanism for the elevated sd-LDL levels seen
in patients with CKD and to addressing their role in CVD as the
leading cause of death in patients with CKD. It also contributes
to scepticism regarding our historically clear-cut view that
grouped cholesterol is either ‘good’ or ‘bad’; its use as a bio-
marker may in fact be measuring more fundamental variables
[12], and our focus may have to narrow to a greater understand-
ing of sub-fractions of lipoprotein transfer lipids. Furthermore,
Fig. 1. Lipid parameters by CKD stage.
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Fig. 2. sd- and g-LDL versus CysC eGFR using the Filler formula [18]. Average age (6 1 SD) was 14.162.5 years for CKD Stage 1; 11.163.6 years for CKD Stage 2;
12.36 4.3 years for CKD Stage 3; 20.46 6.5 for CKD Stage 4; and 13.86 5.9 years for CKD Stage 5.
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our findings in children, echoed by studies in adults, also
strongly indicate that there is a need for a faster, less expensive,
less laborious and more efficient way of measuring the different
classes of LDL, particularly sd-LDL. Comparable to strategies
employed within the SHARP trial [33], our results suggest that
targeting sd-LDL may be a viable option for reducing long-term
cardiovascular risks in paediatric CKD patients, particularly for
those who are in the later stages of CKD. The mechanism is not
well understood. Upregulation of GPIHBP1 in a model of 5/6
nephrectomy in rats and subsequent lipoprotein lipase defi-
ciency which interferes with normal metabolism of VLDL and
chylomicrons may play a role [7]; however, a recent in-depth
review did not offer a clear explanation [34]. The question is
how to lower sd-LDL levels? Possible options are fibrates and
LDL apheresis, however, fibrates are often not well tolerated
and LDL apheresis is invasive and access to this treatment
modality is limited [35]. Newer fibrates such as fenofibrate in a
simvastatin combination have recently demonstrated good
safety profiles in adults and even reduced proteinuria [36].
In summary, this study confirms the specific pattern of sd-
LDL being associated with worsening eGFR in the absence of
any association with g-LDL. The results strongly suggest that
this pattern is CKD specific and not confounded by
Framingham-type risk factors.
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